Diagnosing Deep-vein Thrombosis Early in Critically Ill Patients (DETECT) Trial

What this Trial Is About

This trial investigates whether using twice weekly surveillance ultrasound to detect deep vein thrombosis (DVT) early in critically ill patients can reduce pulmonary embolism (PE) and lower the risk of death within 90 days. It is an open-label, randomized controlled study conducted across multiple centers and countries, focusing on patients admitted to intensive care units (ICU). Participants who qualify will be randomly assigned to either receive ultrasound scans of both lower limbs twice a week or receive standard care without routine ultrasound. The ultrasound is done to detect DVT early and is performed according to the study schedule or treating team discretion. The study compares outcomes between these two groups. During the study, patients will be monitored for up to 90 days, with assessments including ultrasound scans, clinical evaluations for PE and bleeding, and survival status. The main measurement is all-cause mortality at 90 days. Secondary outcomes include the occurrence of proximal DVT within 28 days or until ICU discharge, pulmonary embolism during hospital stay up to 28 days, and clinically important bleeding events up to 90 days. The study involves screening patients within 48 hours of ICU admission and follows them through their hospital stay and beyond as needed.

Diagnosing Deep-vein Thrombosis Early in Critically Ill Patients